NASDAQ:IMVT

Immunovant (IMVT) Stock Forecast, Price & News

$38.39

-1.40 (-3.52%)

(As of 09/29/2023 08:53 PM ET)

Compare

Today's Range: $37.97
▼
$40.74
50-Day Range: $19.59
▼
$39.96
52-Week Range: $5.09
▼
$44.19

Volume: 2.57 million shs
Average Volume: 1.35 million shs
Market Capitalization: $5.02 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.83

Immunovant MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 9.3% Downside
$34.83 Price Target
Short Interest: Bearish
9.70% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.58
Based on 45 Articles This Week
Insider Trading: Selling Shares
$6.46 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.91) to ($1.86) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

Medical Sector

895th out of 970 stocks

Biological Products, Except Diagnostic Industry

147th out of 156 stocks

2.5

Analyst's Opinion

Consensus Rating
Immunovant has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.83, Immunovant has a forecasted downside of 9.3% from its current price of $38.39.
Amount of Analyst Coverage
Immunovant has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
9.70% of the float of Immunovant has been sold short.
Short Interest Ratio / Days to Cover
Immunovant has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Immunovant has recently increased by 4.69%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Immunovant does not currently pay a dividend.
Dividend Growth
Immunovant does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMVT.

2.5

News and Social Media Coverage

News Sentiment
Immunovant has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 45 news articles for Immunovant this week, compared to 3 articles on an average week.
Search Interest
31 people have searched for IMVT on MarketBeat in the last 30 days. This is an increase of 182% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,457,305.00 in company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Immunovant is held by insiders.
Percentage Held by Institutions
42.45% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Immunovant are expected to grow in the coming year, from ($1.91) to ($1.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immunovant is -19.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immunovant is -19.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immunovant has a P/B Ratio of 13.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Immunovant (NASDAQ:IMVT) Stock

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

IMVT Price History

30 days | 90 days | 365 days | Advanced Chart

IMVT Stock News Headlines

October 2, 2023 | americanbankingnews.com

Equities Analysts Set Expectations for Immunovant, Inc.'s Q1 2025 Earnings (NASDAQ:IMVT)

October 1, 2023 | americanbankingnews.com

Immunovant (NASDAQ:IMVT) Stock Price Down 4.4%

October 2, 2023 | Behind the Markets (Ad)

The World's First "$20 Trillion Drug

?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>

September 30, 2023 | americanbankingnews.com

Immunovant (NASDAQ:IMVT) PT Raised to $48.00

September 30, 2023 | americanbankingnews.com

Citigroup Boosts Immunovant (NASDAQ:IMVT) Price Target to $50.00

September 30, 2023 | americanbankingnews.com

Leerink Partnrs Brokers Increase Earnings Estimates for Immunovant, Inc. (NASDAQ:IMVT)

September 29, 2023 | msn.com

Citigroup Maintains Immunovant (IMVT) Buy Recommendation

September 29, 2023 | americanbankingnews.com

Immunovant (NASDAQ:IMVT) Sees Large Volume Increase Following Analyst Upgrade

October 2, 2023 | Stansberry Research (Ad)

U.S. "Shadow Banks" About to Blow up again?

Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.

September 28, 2023 | finance.yahoo.com

Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data

September 28, 2023 | finance.yahoo.com

Immunovant Announces Pricing of $450 Million Common Stock Financing

September 28, 2023 | americanbankingnews.com

Immunovant (NASDAQ:IMVT) Given New $48.00 Price Target at Guggenheim

September 28, 2023 | americanbankingnews.com

Immunovant (NASDAQ:IMVT) Shares Gap Up on Analyst Upgrade

September 27, 2023 | msn.com

Raymond James Upgrades Immunovant (IMVT)

September 27, 2023 | finance.yahoo.com

Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering

September 27, 2023 | msn.com

Immunovant stock rallies for second day, fueled by public offering, drug data

September 27, 2023 | finance.yahoo.com

Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data

September 27, 2023 | seekingalpha.com

Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock

September 27, 2023 | americanbankingnews.com

Truist Financial Reiterates "Buy" Rating for Immunovant (NASDAQ:IMVT)

September 27, 2023 | americanbankingnews.com

Raymond James Upgrades Immunovant (NASDAQ:IMVT) to "Outperform"

September 26, 2023 | msn.com

Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations

September 26, 2023 | finance.yahoo.com

Why Shares of Immunovant Are Soaring on Tuesday

September 26, 2023 | finance.yahoo.com

Immunovant Doubles — And Slugs Argenx — As Autoimmune Disease Battle Heats Up

September 26, 2023 | finance.yahoo.com

Immunovant Announces Proposed Offering of $300 Million of Common Stock

September 26, 2023 | ca.style.yahoo.com

Immunovant shares surge as early antibody treatment data beats expectations

September 26, 2023 | reuters.com

Immunovant shares surge after antibody treatment succeeds in early-stage study

September 26, 2023 | markets.businessinsider.com

Immunovant Stock Receives Buy Rating Following Promising Initial Results of ‘1402 Anti-FcRn Trial

See More Headlines

Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

IMVT Company Calendar

Last Earnings: 8/10/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/03/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IMVT
CUSIP: N/A
CIK: 1764013
Web: www.immunovant.com
Phone: 917-580-3099
Fax: N/A
Employees: 164
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $34.83
High Stock Price Forecast: $50.00
Low Stock Price Forecast: $21.00
Forecasted Upside/Downside: -9.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-210,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.02%
Return on Assets: -56.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.82
Quick Ratio: 6.82

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.78 per share
Price / Book: 13.81

Miscellaneous

Outstanding Shares: 130,670,000
Free Float: 124,400,000
Market Cap: $5.02 billion
Optionable: Not Optionable
Beta: 0.91

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Frank M. Torti M.B.A. (Age 44)
M.D., MBA, Exec. Chairperson of the Board
Comp: $92.5k

Dr. Peter Salzmann M.B.A. (Age 55)
M.D., CEO & Director
Comp: $1.02M

Ms. Eva Renee Barnett M.B.A. (Age 43)
Chief Financial Officer
Comp: $871.07k

Dr. William L. Macias M.D. (Age 65)
Ph.D., Chief Medical Officer
Comp: $719.88k

Dr. Jay S. Stout Ph.D. (Age 60)
Chief Technology Officer

Dr. Chau Cheng M.B.A.
Ph.D., VP of Investor Relations

Mr. Mark S. Levine (Age 50)
Chief Legal Officer & Corp. Sec.

Ms. Lauren Schrier M.B.A.
VP of Marketing

Ms. Christine Blodgett
VP of HR

Dr. Julia G. Butchko Ph.D. (Age 52)
Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IMVT Stock - Frequently Asked Questions

Should I buy or sell Immunovant stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMVT shares.
View IMVT analyst ratings or view top-rated stocks.
What is Immunovant's stock price forecast for 2023?: 12 Wall Street analysts have issued 12-month target prices for Immunovant's shares. Their IMVT share price forecasts range from $21.00 to $50.00. On average, they expect the company's stock price to reach $34.83 in the next year. This suggests that the stock has a possible downside of 9.3%.
View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts.
How have IMVT shares performed in 2023?: Immunovant's stock was trading at $17.75 at the start of the year. Since then, IMVT shares have increased by 116.3% and is now trading at $38.39.
View the best growth stocks for 2023 here.
When is Immunovant's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023.
View our IMVT earnings forecast.
How were Immunovant's earnings last quarter?: Immunovant, Inc. (NASDAQ:IMVT) issued its earnings results on Thursday, August, 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.03.
What ETFs hold Immunovant's stock?: ETFs with the largest weight of Immunovant (NASDAQ:IMVT) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Principal Healthcare Innovators ETF (BTEC).IQ U.S. Small Cap ETF (CSML).

What other stocks do shareholders of Immunovant own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).
What is Immunovant's stock symbol?: Immunovant trades on the NASDAQ under the ticker symbol "IMVT."
How do I buy shares of Immunovant?: Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Immunovant's stock price today?: One share of IMVT stock can currently be purchased for approximately $38.39.
How much money does Immunovant make?: Immunovant (NASDAQ:IMVT) has a market capitalization of $5.02 billion. The company earns $-210,960,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.
How many employees does Immunovant have?: The company employs 164 workers across the globe.
How can I contact Immunovant?: Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The official website for the company is www.immunovant.com. The company can be reached via phone at 917-580-3099 or via email at info@immunovant.com.

This page (NASDAQ:IMVT) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immunovant (IMVT) Stock Forecast, Price & News

Immunovant MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Immunovant (NASDAQ:IMVT) Stock

IMVT Price History

IMVT Stock News Headlines

IMVT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IMVT Stock - Frequently Asked Questions

Overall MarketRank^™